Steven Bellon
Director Técnico/Científico/I+D en FOGHORN THERAPEUTICS INC. .
Fortuna: 1 M $ al 31/05/2024
Cargos activos de Steven Bellon
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director Técnico/Científico/I+D | 10/01/2022 | - |
| Corporate Officer/Principal | 01/06/2016 | 10/01/2022 |
Historial de carrera de Steven Bellon
Antiguos cargos conocidos de Steven Bellon.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/09/2008 | 01/05/2016 |
| Corporate Officer/Principal | 01/09/2008 | 01/05/2016 |
Formación de Steven Bellon.
| Haverford College | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
Operativa
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 2 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Steven Bellon
- Experiencia
